Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Prenatal diagnosis Stories

2012-10-03 02:27:43

REDWOOD CITY, Calif., Oct. 3, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced the addition of three industry veterans to its senior leadership team. Dr. Vance Vanier joins Verinata as President, Dr. Keith Jones as Senior Vice President of Research and Development and Dr. Suchetta Bhatt as Vice President of Genetics. (Logo: http://photos.prnewswire.com/prnh/20120425/SF94380LOGO) "As we expand our...

2012-09-24 02:27:17

SAN JOSE, Calif., Sept. 24, 2012 /PRNewswire/ -- A new study published in the journal Ultrasound in Obstetrics and Gynecology, is the largest study to date of non-invasive prenatal testing (NIPT) for detecting fetal trisomy 13 (T13) and provides further evidence of the Harmony Prenatal Test's utility for detection of genetic conditions. T13 causes Patau syndrome and affects approximately one in 16,000 newborns. T13 is also associated with a high rate of spontaneous miscarriage. (Logo:...

2012-09-07 06:24:04

Early Detection of Heart Disease in Fetus Helps in Planning Care, but May Increase Maternal Anxiety, Depression PHILADELPHIA, Sept. 7, 2012 /PRNewswire-USNewswire/ -- Expectant mothers who learn from prenatal diagnosis that they are carrying a fetus with a congenital heart defect (CHD) commonly suffer post-traumatic stress, depression and anxiety. However, a healthy relationship with one's partner and positive coping mechanisms can reduce this intense stress, according to new research...

2012-09-05 02:33:03

SAN JOSE, Calif., Sept. 5, 2012 /PRNewswire/ -- A study just published in the American Journal of Obstetrics and Gynecology (The Gray Journal) provides substantial new evidence that the Harmony Prenatal Test, a specific type of non-invasive prenatal test (NIPT), is effective in a general screening population. In this study, the test detected all cases of fetal trisomy 21 and 18 at a false-positive rate of 0.1 percent. (Photo: http://photos.prnewswire.com/prnh/20120905/NE68146LOGO ) The...

2012-08-28 02:28:06

SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that its wholly-owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), has completed several international distribution agreements that will expand access to the MaterniT21 PLUS testing service outside the United States. Agreements in Asia cover Japan and Hong Kong; in Europe cover the...

2012-08-27 02:25:42

SAN JOSE, Calif., Aug. 27, 2012 /PRNewswire/ -- A study published in The Journal of Maternal-Fetal and Neonatal Medicine demonstrates that the fraction of fetal cell-free DNA (cfDNA) in maternal blood is unaffected by the mother's presumed risk for trisomy, offering support for the use of non-invasive prenatal testing (NIPT) for detecting genetic conditions such as Down syndrome in a broad patient population. Lead and senior authors of the study were Dr. Herb Brar, Director of Riverside...

2012-08-10 10:22:47

PHILADELPHIA, Aug. 10, 2012 /PRNewswire-USNewswire/ -- Thirty years ago the idea of performing fetal surgery seemed more like science fiction than reality. Today, however, highly sophisticated surgical teams regularly repair spina bifida and other birth defects before birth, and fetal therapy is recognized as one of the most promising fields in pediatric medicine. (Photo: http://photos.prnewswire.com/prnh/20120810/DC56010) Spina bifida is the most common birth defect of the central nervous...

2012-07-24 02:29:11

SAN JOSE, Calif., July 24, 2012 /PRNewswire/ -- Ariosa Diagnostics, Inc., a molecular diagnostics company, announced today the completion of the first clinical study to evaluate non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) in a general population of pregnant women. The patients of this study were from a single large obstetrical practice over a specified period of time and represent an average-risk population for that center. The study's significance is that it evaluates...

2012-07-06 10:21:47

SAN DIEGO, July 6, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today confirmed that the United States District Court for the Northern District of California has denied a motion by Sequenom for a preliminary injunction against Ariosa Diagnostics. "While obviously a disappointing preliminary outcome in our efforts to enforce an issued US patent against infringement, yesterday's decision is by no means a final...

2012-07-02 02:23:58

REDWOOD CITY, Calif., July 2, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced that its non-invasive verifi(TM) prenatal test can now be used to detect Turner syndrome (monosomy X or XO), a genetic condition in which a person has one X chromosome and is missing a second sex chromosome. Turner syndrome affects approximately one in every 2,000 female births. (Logo:...